$SWKH
SWK Holdings Corp

2022 Q4 Form 10-Q Financial Statement

#000155278122000629 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $9.797M $13.61M $9.560M
YoY Change -34.49% 42.41% -10.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.928M $4.349M $3.580M
YoY Change 56.21% 21.48% 41.5%
% of Gross Profit
Research & Development $1.779M $1.792M $2.487M
YoY Change 0.51% -27.95% 110.76%
% of Gross Profit
Depreciation & Amortization $635.0K $634.0K $812.0K
YoY Change -16.01% -21.92% -69.7%
% of Gross Profit
Operating Expenses $8.342M $1.792M $6.879M
YoY Change 31.97% -73.95% 7.65%
Operating Profit $6.757M $2.628M
YoY Change 157.12%
Interest Expense -$5.834M $82.00K $75.00K
YoY Change 2732.04% 9.33% -120.27%
% of Operating Profit 1.21% 2.85%
Other Income/Expense, Net
YoY Change
Pretax Income -$4.379M $8.558M $2.756M
YoY Change -151.95% 210.52% -29.15%
Income Tax -$7.211M $1.942M $513.0K
% Of Pretax Income 22.69% 18.61%
Net Earnings $2.832M $6.616M $2.243M
YoY Change -55.24% 194.96% -48.32%
Net Earnings / Revenue 28.91% 48.6% 23.46%
Basic Earnings Per Share $0.52 $0.18
Diluted Earnings Per Share $0.22 $0.51 $174.4K
COMMON SHARES
Basic Shares Outstanding 12.82M shares 12.83M shares 12.80M shares
Diluted Shares Outstanding 12.85M shares 12.86M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.156M $19.90M $21.41M
YoY Change -85.98% -7.04% 103.87%
Cash & Equivalents $6.156M $19.40M $18.64M
Short-Term Investments $500.0K $2.767M
Other Short-Term Assets $1.114M $1.189M $1.101M
YoY Change -35.5% 7.99% -42.05%
Inventory
Prepaid Expenses
Receivables $3.094M $7.384M $2.254M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.36M $28.47M $24.76M
YoY Change -78.15% 14.99% 45.65%
LONG-TERM ASSETS
Property, Plant & Equipment $5.840M $5.945M $5.791M
YoY Change 1.06% 2.66% 70.32%
Goodwill $8.404M $8.404M
YoY Change 0.0%
Intangibles $8.190M $8.615M
YoY Change -17.8%
Long-Term Investments $76.00K $3.579M $3.689M
YoY Change -97.89% -2.98% 1129.67%
Other Assets $1.742M $1.802M $27.33M
YoY Change -11.57% -93.41% -4.45%
Total Long-Term Assets $289.3M $263.8M $251.9M
YoY Change 22.96% 4.74% 5.03%
TOTAL ASSETS
Total Short-Term Assets $10.36M $28.47M $24.76M
Total Long-Term Assets $289.3M $263.8M $251.9M
Total Assets $299.6M $292.3M $276.6M
YoY Change 6.0% 5.66% 7.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.902M $4.746M $4.494M
YoY Change -23.29% 5.61% 24.83%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.445M $0.00 $8.000K
YoY Change 30462.5% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.347M $4.746M $4.502M
YoY Change 24.57% 5.42% 25.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.145M $1.544M $11.45M
YoY Change 18.9% -86.51% -34.58%
Total Long-Term Liabilities $2.145M $1.544M $11.45M
YoY Change 18.9% -86.51% -34.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.347M $4.746M $4.502M
Total Long-Term Liabilities $2.145M $1.544M $11.45M
Total Liabilities $19.69M $14.82M $15.95M
YoY Change 27.63% -7.09% -24.4%
SHAREHOLDERS EQUITY
Retained Earnings -$4.151B -$4.154B
YoY Change -0.32%
Common Stock $12.00K $13.00K
YoY Change -7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $279.9M $277.4M $260.7M
YoY Change
Total Liabilities & Shareholders Equity $299.6M $292.3M $276.6M
YoY Change 6.0% 5.66% 7.72%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $2.832M $6.616M $2.243M
YoY Change -55.24% 194.96% -48.32%
Depreciation, Depletion And Amortization $635.0K $634.0K $812.0K
YoY Change -16.01% -21.92% -69.7%
Cash From Operating Activities $3.095M $1.712M $3.822M
YoY Change -72.42% -55.21% -6.32%
INVESTING ACTIVITIES
Capital Expenditures $103.0K -$83.00K -$206.0K
YoY Change -151.24% -59.71% -76.05%
Acquisitions
YoY Change
Other Investing Activities -$15.64M -$36.59M $8.396M
YoY Change -200.46% -535.79% -326.31%
Cash From Investing Activities -$15.74M -$36.67M $8.190M
YoY Change -202.44% -547.77% -278.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -594.0K -759.0K 8.000K
YoY Change -74.92% -9587.5% -100.11%
NET CHANGE
Cash From Operating Activities 3.095M 1.712M 3.822M
Cash From Investing Activities -15.74M -36.67M 8.190M
Cash From Financing Activities -594.0K -759.0K 8.000K
Net Change In Cash -13.24M -35.72M 12.02M
YoY Change -154.67% -397.16% -253.12%
FREE CASH FLOW
Cash From Operating Activities $3.095M $1.712M $3.822M
Capital Expenditures $103.0K -$83.00K -$206.0K
Free Cash Flow $2.992M $1.795M $4.028M
YoY Change -73.81% -55.44% -18.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
13970000 usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75254
dei City Area Code
CityAreaCode
972
dei Entity Central Index Key
EntityCentralIndexKey
0001089907
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2021Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
CY2022Q3 swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
CY2021Q3 swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39184
dei Entity Registrant Name
EntityRegistrantName
SWK Holdings Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Local Phone Number
LocalPhoneNumber
687-7250
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Central Index Key
EntityCentralIndexKey
0001089907
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39184
dei Entity Registrant Name
EntityRegistrantName
SWK Holdings Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0435679
dei Entity Address Address Line1
EntityAddressAddressLine1
14755 Preston Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75254
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
687-7250
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12820349 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19399000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42863000 usd
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
7384000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
1034000 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1189000 usd
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0435679
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1727000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
14755 Preston Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12820349 shares
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
1803000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
500000 usd
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
181553000 usd
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
7384000 usd
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
1803000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
500000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19399000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42863000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
28472000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47427000 usd
CY2022Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
212959000 usd
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
181553000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119000 usd
CY2022Q3 us-gaap Cost Method Investments
CostMethodInvestments
3491000 usd
CY2021Q4 us-gaap Cost Method Investments
CostMethodInvestments
3491000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17350000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20539000 usd
CY2022Q3 swkh Warrant Assets
WarrantAssets
5140000 usd
CY2021Q4 swkh Warrant Assets
WarrantAssets
3419000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8615000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9964000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
8404000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
8404000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5945000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5779000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1802000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1970000 usd
CY2022Q3 us-gaap Assets
Assets
292266000 usd
CY2021Q4 us-gaap Assets
Assets
282665000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4746000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5087000 usd
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
8000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4746000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5095000 usd
CY2022Q3 swkh Contingent Consideration Payable
ContingentConsiderationPayable
8530000 usd
CY2021Q4 swkh Contingent Consideration Payable
ContingentConsiderationPayable
8530000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1544000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1804000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
14820000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
15429000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12835304 shares
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119000 usd
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12835304 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12836133 shares
CY2022Q3 us-gaap Cost Method Investments
CostMethodInvestments
3491000 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12836133 shares
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
1034000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1189000 usd
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1727000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Assets Current
AssetsCurrent
28472000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47427000 usd
CY2022Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
212959000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Cost Method Investments
CostMethodInvestments
3491000 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2021Q4 swkh Warrant Assets
WarrantAssets
3419000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292266000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
282665000 usd
CY2022Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8502000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8615000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9964000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
678000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17350000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20539000 usd
CY2022Q3 swkh Warrant Assets
WarrantAssets
5140000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
8404000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
8404000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5945000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5779000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1802000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1970000 usd
CY2022Q3 us-gaap Assets
Assets
292266000 usd
CY2021Q4 us-gaap Assets
Assets
282665000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4746000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5087000 usd
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
8000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4746000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5095000 usd
CY2022Q3 swkh Contingent Consideration Payable
ContingentConsiderationPayable
8530000 usd
CY2021Q4 swkh Contingent Consideration Payable
ContingentConsiderationPayable
8530000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1544000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1804000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
14820000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
15429000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12835304 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12835304 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12836133 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12836133 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4431270000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4431719000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4431270000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4431719000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4153837000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4164496000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
277446000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
267236000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292266000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
282665000 usd
CY2022Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8502000 usd
CY2021Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
9373000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
25745000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
29857000 usd
CY2022Q3 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
5111000 usd
CY2021Q3 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
187000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
5461000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
10846000 usd
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
1000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
481000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
496000 usd
CY2022Q3 us-gaap Revenues
Revenues
13614000 usd
CY2021Q3 us-gaap Revenues
Revenues
9560000 usd
us-gaap Revenues
Revenues
31687000 usd
us-gaap Revenues
Revenues
41199000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
82000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
53000 usd
us-gaap Interest Expense
InterestExpense
242000 usd
us-gaap Interest Expense
InterestExpense
292000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1792000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2487000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5173000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5577000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
634000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1964000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3305000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4349000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3580000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10527000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9825000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6757000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2628000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
13781000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
22347000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
13000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
342000 usd
CY2021Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
9373000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4153837000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4164496000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
277446000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
267236000 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1788000 usd
CY2021Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-214000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
623000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
25745000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
29857000 usd
CY2022Q3 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
5111000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-534000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1557000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8558000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2756000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
13870000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
24582000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1942000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
513000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3211000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4980000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
2243000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12851000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12871000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12834000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
267236000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
85000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
3478000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
270799000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
166000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
565000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
271530000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
59000 usd
CY2022Q3 swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-160000 usd
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-599000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
6616000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
277446000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
240512000 usd
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
177000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3389000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
244078000 usd
CY2021Q3 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
187000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
5461000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
10846000 usd
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
1000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
481000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
496000 usd
CY2022Q3 us-gaap Revenues
Revenues
13614000 usd
CY2021Q3 us-gaap Revenues
Revenues
9560000 usd
us-gaap Revenues
Revenues
31687000 usd
us-gaap Revenues
Revenues
41199000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
82000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
53000 usd
us-gaap Interest Expense
InterestExpense
242000 usd
us-gaap Interest Expense
InterestExpense
292000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1792000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2487000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5173000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5577000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
634000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1964000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3305000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4349000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3580000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10527000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9825000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6757000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2628000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
13781000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
22347000 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1788000 usd
CY2021Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-214000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
623000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
678000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
13000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
342000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-534000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1557000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8558000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2756000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
13870000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
24582000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1942000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
513000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3211000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
187000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-767000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-17833000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
258235000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
192000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2243000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
260670000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
26000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3189000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
4842000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-623000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-678000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-534000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
1557000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
1357000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
2016000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
3335000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
698000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
310000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
556000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1964000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3305000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-5581000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-343000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
76000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
371000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-603000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
542000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5107000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23072000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
71750000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
20100000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
43938000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
31162000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
31000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
43000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
877000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-171000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-164000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27804000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10392000 usd
swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-160000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-8000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-11750000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4980000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
2243000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12851000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12871000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12834000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
267236000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
85000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
3478000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
270799000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
166000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
565000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
271530000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
59000 usd
CY2022Q3 swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-160000 usd
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-599000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
6616000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
277446000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
240512000 usd
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
177000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3389000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
244078000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
187000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
13970000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
258235000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
192000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2243000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
260670000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
26000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
6083000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
599000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3189000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23464000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
4842000 usd
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
61000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
39000 shares
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-623000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-678000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-534000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
1557000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
1357000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
2016000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
3335000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
698000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
310000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
556000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1964000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3305000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-5581000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-343000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
76000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
371000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-603000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
542000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5107000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23072000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
71750000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
20100000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
43938000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
31162000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
31000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
43000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
877000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-171000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-164000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27804000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10392000 usd
swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-160000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-8000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-11750000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
6083000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
599000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-767000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-17833000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23464000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15631000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42863000 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3008000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19399000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18639000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15631000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42863000 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3008000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19399000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18639000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zDxEDsfm6xG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b><i><span id="xdx_867_zhXZaYdripj4">Use of Estimates</span></i></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of accounts receivable; impairment of finance receivables; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</p>
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19000 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 number
swkh Disclosure Net Income Per Share Details Abstract
DisclosureNetIncomePerShareDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_z7R84XIKkeZ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td/><td style="font-size: 10pt; padding-bottom: 1pt"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20220701__20220930_zBSVdSTRKaXj" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20210101__20210331_zrUN1Jh6axh2" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/><td style="font-size: 10pt; padding-bottom: 1pt"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_49C_20220101__20220930_ziKZLDrbIUAb" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20210101__20210930_zZ69FhNARZy5" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">Numerator:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_402_eus-gaap--ProfitLoss_zR5Ubr8jY0Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; padding-left: 6pt">Net income</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">6,616</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">2,243</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">10,659</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">19,602</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zj0BKLhLbQz3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 6pt">Weighted-average shares outstanding</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,832</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,798</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,832</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,796</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zExRcsQrvoH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Effect of dilutive securities</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zVC1Rai2B3Zb" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 6pt">Weighted-average diluted shares</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,851</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,859</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,871</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,834</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zifiXRQKkl7j" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Basic net income per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.52</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.18</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.83</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.53</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareDiluted_pid_zxxHZ6Gy4GG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Diluted net income per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.51</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.17</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.83</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.53</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2243000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12871000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12832000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
38000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12851000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12834000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
186000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
367000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
268000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
390000 shares
swkh Disclosure Finance Receivables Net Details Abstract
DisclosureFinanceReceivablesNetDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_zRlYvK7L4Kc6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20220930_zIEF7EmGCgza" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20211231_zMfaTzDQAE8b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zb0EwsfWldNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left; text-indent: -9pt; padding-left: 9pt">Term loans</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">180,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z6l2K6w8VST5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zNDkA9Xn87a3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,941</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zn9cZerstJWc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,357</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,388</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zqrya6ORvM48" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
221316000 usd
CY2021Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
189941000 usd
CY2022Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8357000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8388000 usd
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
212959000 usd
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
181553000 usd
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
39000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
38000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12851000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zDxEDsfm6xG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b><i><span id="xdx_867_zhXZaYdripj4">Use of Estimates</span></i></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of accounts receivable; impairment of finance receivables; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</p>
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
61000 shares
swkh Disclosure Finance Receivables Net Details2 Abstract
DisclosureFinanceReceivablesNetDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zuO8V6qiWrW3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20220930__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zz0jKNgKTt8l" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49C_20220930__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zGoaQRkeBsG6" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20220930_zyYyjGfIT8Pe" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zZaexWPFIxjf" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zKjhlkIjuiIi" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20211231_zbJEhNnwOYNc" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonaccrual</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performing</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonaccrual</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performing</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zExDvMHle4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Term loans</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">9,789</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">170,748</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">180,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">118,024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zW8W8HpmFpj6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Royalty purchases, net of credit loss allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,037</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,422</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,362</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,879</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,241</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zF8oNX7PYxHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 6pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
212959000 usd
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
181553000 usd
swkh Disclosure Marketable Investments Details Abstract
DisclosureMarketableInvestmentsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureMarketableInvestmentsDetailsAbstract_pn3n3_zv4CsPUnCj38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49C_20220930_zVzlRvKN0gu3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20211231_zrQF5LmvYet2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr id="xdx_409_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_maIzegN_zkKQKQmHgFq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate debt securities</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketableSecurities_iI_maIzegN_zyFkRaL9Iv48" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Investments_iTI_mtIzegN_zZHfTKWsNKKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 15.75pt">Total marketable investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">588</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
500000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
1034000 usd
CY2022Q3 us-gaap Investments
Investments
588000 usd
CY2021Q4 us-gaap Investments
Investments
1153000 usd
swkh Disclosure Marketable Investments Details2 Abstract
DisclosureMarketableInvestmentsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureMarketableInvestmentsDetails2Abstract_pn3n3_zqaX80DHsbBh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 2)"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Amortized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Cost</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Gross </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Gains</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Gross </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Loss</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 47%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zB6Oq59WxC4j" style="width: 10%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zsoEwSl9EVFl" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zFAfn88sJNPk" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecurities_iI_c20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zfWoXAiyiHEi" style="width: 10%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zkYUWlPP19ec" style="text-align: right">119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWNIRYEs7iSb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zyiiB0TCO5fj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleSecurities_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zVi56Gzc6tme" style="text-align: right">119</td><td style="text-align: left"> </td></tr> </table>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 number
swkh Disclosure Net Income Per Share Details Abstract
DisclosureNetIncomePerShareDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_z7R84XIKkeZ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td/><td style="font-size: 10pt; padding-bottom: 1pt"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20220701__20220930_zBSVdSTRKaXj" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20210101__20210331_zrUN1Jh6axh2" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/><td style="font-size: 10pt; padding-bottom: 1pt"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_49C_20220101__20220930_ziKZLDrbIUAb" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/> <td id="xdx_497_20210101__20210930_zZ69FhNARZy5" style="font-size: 10pt; text-align: center"/> <td style="font-size: 10pt; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">Numerator:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_402_eus-gaap--ProfitLoss_zR5Ubr8jY0Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left; padding-left: 6pt">Net income</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">6,616</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">2,243</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">10,659</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">19,602</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zj0BKLhLbQz3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 6pt">Weighted-average shares outstanding</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,832</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,798</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,832</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">12,796</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zExRcsQrvoH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Effect of dilutive securities</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zVC1Rai2B3Zb" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 6pt">Weighted-average diluted shares</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,851</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,859</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,871</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,834</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zifiXRQKkl7j" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Basic net income per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.52</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.18</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.83</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.53</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareDiluted_pid_zxxHZ6Gy4GG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Diluted net income per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.51</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.17</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.83</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.53</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2243000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
swkh Disclosure Marketable Investments Details3 Abstract
DisclosureMarketableInvestmentsDetails3Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureMarketableInvestmentsDetails3Abstract_pn3n3_zveH3MNHtoD9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 3)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Unrealized net gain (loss) on equity securities reflected in the unaudited condensed consolidated statements of income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220701__20220930_zxlOGe33KxPb" style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210701__20210930_z7lM1XFXEW3d" style="width: 9%; text-align: right">342</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20220930_znt6PgayNuz2" style="width: 9%; text-align: right">(534</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20210930_zWoThvY8FO93" style="width: 9%; text-align: right">1,557</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
13000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
342000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-534000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1557000 usd
swkh Disclosure Intangible Assets Details Abstract
DisclosureIntangibleAssetsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zK7zX30gi3c1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-size: 10pt">Licensing Agreement<sup id="xdx_F44_z1prfJbPrjOg">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zWmNXuk9g077" style="width: 5%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zuMwzbt86fW8" style="width: 5%; text-align: right">21,096</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zeyZXJ3JL7V8" style="width: 5%; text-align: right">8,304</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zUr5tCsVtNqb" style="width: 5%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zWqTRVG8JJt1" style="width: 5%; text-align: right">19,780</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zs8xRMD63909" style="width: 5%; text-align: right">9,620</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcFbX7ksyHdb" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcWtbZLDX0Tb" style="text-align: right">65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypqG3lP37se" style="text-align: right">145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zL7cgGBLFpPj" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zAvz5ZLaCdJ3" style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zuGEBLoL77Ad" style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyoh415KPEVh" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zL87bbbGkyak" style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6dEb4CWLMN7" style="border-bottom: Black 1pt solid; text-align: right">166</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNYQc9KNO8ih" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zmiPzAlS9eW2" style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znimLEFS7p88" style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930_zPMw1mIoG54f" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930_zlgVMqRBRjG3" style="border-bottom: Black 2.5pt double; text-align: right">21,235</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20220930_zlrhluWs60Te" style="border-bottom: Black 2.5pt double; text-align: right">8,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231_zU0sXUVzEnx" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zyeSyebxMTZe" style="border-bottom: Black 2.5pt double; text-align: right">19,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20211231_zHGeK0WfM5j3" style="border-bottom: Black 2.5pt double; text-align: right">9,964</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span id="xdx_F05_zlQn9eUd1Qra" style="font-size: 8pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F1D_zuiNSrej2QWb" style="font-size: 8pt">Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA<sup>TM</sup> in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.</span></td> </tr></table>
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21235000 usd
CY2022Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
8615000 usd
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19886000 usd
CY2021Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
9964000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2900000 usd
swkh Disclosure Intangible Assets Details2 Abstract
DisclosureIntangibleAssetsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zAyAYBn4dHof" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20220930_z1LLX2Ll5LSd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_z8njqN3uwKdb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%">Remainder of 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">426</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zRrpxh6lQns3" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">2023</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zO7lFdfv7Sn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">2024</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zJgI27JTlard" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">2025</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zIjTbV1LiVEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">2026</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_zfrBa7ki5Jah" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,788</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zri3Ij75FPD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 6pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
426000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1703000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1546000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1076000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1076000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2788000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8615000 usd
CY2021Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
8500000 usd
CY2022Q3 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
8500000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12871000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12834000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
186000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
367000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
268000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
390000 shares
swkh Disclosure Finance Receivables Net Details Abstract
DisclosureFinanceReceivablesNetDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_zRlYvK7L4Kc6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20220930_zIEF7EmGCgza" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20211231_zMfaTzDQAE8b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zb0EwsfWldNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left; text-indent: -9pt; padding-left: 9pt">Term loans</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">180,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z6l2K6w8VST5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zNDkA9Xn87a3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,941</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zn9cZerstJWc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,357</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,388</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zqrya6ORvM48" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
221316000 usd
CY2021Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
189941000 usd
CY2022Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8357000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8388000 usd
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
212959000 usd
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
181553000 usd
swkh Disclosure Fair Value Measurements Details5 Abstract
DisclosureFairValueMeasurementsDetails5Abstract
<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_zluFICpcHkW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20220930__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zdgLPrxXxa8c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20220930__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zWy7KRyduKza" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z47bZgnQYe36" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK7kAiQB6Ow5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49C_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1QhLOwYNoWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr> <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zmyHAlMozf7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z4mQgulvUwe9" style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansReceivableFairValueDisclosure_i01I_zRgphdbR2h6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentsFairValueDisclosure_i01I_zxtSy9W0IOG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zFfXh7VsI7pd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAbstract_iB_zDgfQGnHK25k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ContingentConsiderationPayable_i01I_zrOBqoMx6DSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_z7gXcs9uBTcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zk01Je4oUxW6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsr5oTcNRo4l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLqnyeGEL9M6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZxzxRAvuzD" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr> <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zuEea5mcJME8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z2DXxKTVmf5b" style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansReceivableFairValueDisclosure_i01I_z0g9Sgofqtcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0912">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InvestmentsFairValueDisclosure_i01I_zyZA3zM5912h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAssetsFairValueDisclosure_i01I_za7VQ2hFpii1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0923">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesAbstract_iB_zKG4xeuipIh3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContingentConsiderationPayable_i01I_zfSkAAENqGi7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Finance Receivables Net Details2 Abstract
DisclosureFinanceReceivablesNetDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zuO8V6qiWrW3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20220930__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zz0jKNgKTt8l" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49C_20220930__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zGoaQRkeBsG6" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20220930_zyYyjGfIT8Pe" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zZaexWPFIxjf" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zKjhlkIjuiIi" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20211231_zbJEhNnwOYNc" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonaccrual</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performing</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonaccrual</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performing</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zExDvMHle4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Term loans</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">9,789</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">170,748</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">180,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">118,024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zW8W8HpmFpj6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Royalty purchases, net of credit loss allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,037</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,422</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,362</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,879</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,241</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zF8oNX7PYxHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 6pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
212959000 usd
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
181553000 usd
swkh Disclosure Marketable Investments Details Abstract
DisclosureMarketableInvestmentsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureMarketableInvestmentsDetailsAbstract_pn3n3_zv4CsPUnCj38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49C_20220930_zVzlRvKN0gu3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20211231_zrQF5LmvYet2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr id="xdx_409_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_maIzegN_zkKQKQmHgFq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate debt securities</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketableSecurities_iI_maIzegN_zyFkRaL9Iv48" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Investments_iTI_mtIzegN_zZHfTKWsNKKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 15.75pt">Total marketable investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">588</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
500000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
1034000 usd
CY2022Q3 us-gaap Investments
Investments
588000 usd
CY2021Q4 us-gaap Investments
Investments
1153000 usd
swkh Disclosure Marketable Investments Details2 Abstract
DisclosureMarketableInvestmentsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureMarketableInvestmentsDetails2Abstract_pn3n3_zqaX80DHsbBh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 2)"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Amortized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Cost</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Gross </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Gains</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Gross </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Loss</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 47%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zB6Oq59WxC4j" style="width: 10%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zsoEwSl9EVFl" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zFAfn88sJNPk" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecurities_iI_c20220930__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zfWoXAiyiHEi" style="width: 10%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zkYUWlPP19ec" style="text-align: right">119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWNIRYEs7iSb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zyiiB0TCO5fj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleSecurities_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zVi56Gzc6tme" style="text-align: right">119</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Commitments And Contingencies Details Abstract
DisclosureCommitmentsAndContingenciesDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zehJQ1JNPd86" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"/><td/> <td style="text-align: left"/><td id="xdx_480_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zNErjL9w8bK1" style="text-align: right"/><td style="text-align: left"/></tr> <tr id="xdx_418_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AziyoBiologicsIncMember_zHUhl0Rvqmsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Aziyo Biologics, Inc.</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExeevoIncMember_zG7t6ujfSXol" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exeevo, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedMinderSystemsIncMember_zKXeCsWwVOS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">MedMinder Systems, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrioHealthcareLtdLoanMember_zcj95hAPwVqb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Trio Healthcare Ltd. Loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1.4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zLy5nAVf1J16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 15pt">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details Abstract
DisclosureFairValueMeasurementsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zgNsL7LcTh69" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kym4jozEb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRvOkVxGBaz6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49A_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z8JpOiT4lbv3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjnfNuilXj41" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zSo1MTPD4S59" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zwc58hDNugNc" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">Warrant assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zbfj2mOEPKa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0762">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zM3aJMTVqMOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_zyNmApykTbUk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_495_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPoMZQigPIP" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4m4rM7WBtcb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zznThFXqX19j" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE7Rs79yxDO9" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_401_ecustom--FinancialAssetsAbstract_iB_z4lcoFdz0bm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WarrantAssets_i01I_pn3n3_zARKl8wU721i" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">Warrant assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zeFOe4u8JUz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FinancialLiabilitiesAbstract_iB_zCsjJzHH1EY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z0tx5HHum2Dh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0796">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details2 Abstract
DisclosureFairValueMeasurementsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zcHzJG7hG99d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49F_20220101__20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zl6Qzmzquxa5" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_497_20210101__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpSdLPytuBhe" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td></tr> <tr id="xdx_401_ecustom--WarrantAssets_iS_zNOUl4GuI4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Fair value - December 31, 2021</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 32%">Fair value - December 31, 2020</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WarrantIssuances_zwh9YsaA8La9" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,098</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WarrantsCanceled_zvVJETzA36Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">—</span></td><td style="text-align: left"> </td><td> </td> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_zPyVkjPCfXVf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">623</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantAssets_iE_z3kQmfbmwg36" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value - September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details3 Abstract
DisclosureFairValueMeasurementsDetails3Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_zRukTnGL9V9g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left">Dividend rate range</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z9t3ciIW5P2l">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zRmCddQ9nt3b"><span style="-sec-ix-hidden: xdx2ixbrl0823">—</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5OiMKygyGSj">4.0%</span> to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zL67Azf1L5F9">4.3%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ztBxqdTzxIU1">0.97%</span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zgskL4gtK2s1">1.44%</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"> <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z1SlK6ngUGTd" title="::XDX::P1Y9M18D">1.8</span> to <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zv2dr8bQmXX1" title="::XDX::P6Y10M24D">6.9</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUGo3Cdo1nW" title="::XDX::P2Y7M6D">2.6</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zZnFB87NuPsg" title="::XDX::P7Y">7.0</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ztttiiX1FL36">54.8%</span> to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zwQzhDkXxvX1">139.4%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zkvI7Uu81DFj">60.2%</span> to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zbUSmoOrFFdc">142.0%</span></span></td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details4 Abstract
DisclosureFairValueMeasurementsDetails4Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zWg6TR2SUDp5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zVOCVYBsVjkj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_ze2hMWpFjAoj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zmmIER4zuUea" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zBxMMxaW8z7b" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_43B_c20220930_eus-gaap--InvestmentsFairValueDisclosure_iI_z91Gfg0F53Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 47%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="vertical-align: bottom; width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,071</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,071</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left"> </td><td style="vertical-align: bottom; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20211231_eus-gaap--InvestmentsFairValueDisclosure_iI_zUEb0txOiOOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="vertical-align: bottom; font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Revenue Recognition Details Abstract
DisclosureRevenueRecognitionDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_ztnH6eYmRjq7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td/><td style="padding-bottom: 1pt"/> <td style="text-align: center"/> <td id="xdx_49D_20220701__20220930_zdjiRNYgl3Yh" style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td id="xdx_491_20210701__20210930_zQwWR1vRryYf" style="text-align: center"/> <td style="text-align: center"/><td style="padding-bottom: 1pt"/> <td style="text-align: center"/> <td id="xdx_49D_20220101__20220930_zpeNVcfR5my3" style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td id="xdx_490_20210101__20210930_zGA6k0vDTSpa" style="text-align: center"/> <td style="text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z4KDjTJGUw7f" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">License Agreement<sup id="xdx_F4C_zFaZggirAYbh">(1)</sup></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,103</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,235</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zkKVLp6kcNc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">556</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zoX5f5oMPYcd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td id="xdx_F0A_z3ZTGT0bgK33" style="width: 20pt">(1)</td> <td id="xdx_F18_zqnu4xb0n6Qa">$<span id="xdx_90B_eus-gaap--RevenueRecognitionMilestoneMethodRevenueRecognized_dm_c20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--EnterisLicenseAgreementMember_zKR7ers9iFRh">5.0 million</span> of milestone revenue related to Enteris’s License Agreement with Cara was received during the nine months ended September 30, 2022.</td></tr> </table>
swkh Disclosure Revenue Recognition Details2 Abstract
DisclosureRevenueRecognitionDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_zeJFfJwX4gRc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_490_20220930_zFLCsCFKZbbh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20211231_zGY096OVsGK5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zOMsHWPehNd1" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">8</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">185</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_znnbjY5BjSqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
8000 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
185000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
185000 usd
swkh Disclosure Segment Information Details Abstract
DisclosureSegmentInformationDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_zGUXhgt5o8Q5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td><b/></td><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_491_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zipfofcpN65k" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_497_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zogLvKUeRVw8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_493_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zmEbE7qtXlH9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_492_20220701__20220930_z5VzOdv2hvyl" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_40E_ecustom--RevenuesExcludingOtherRevenue_z6j2EcB6ljil" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,502</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueNotFromContractWithCustomerOther_zKkyeWAQ4jM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpense_zsmrVLQ2kjS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zqs04zPAfnY5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DepreciationAndAmortization_z27gtj4l6o4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">634</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_z2NdSEDrqzjf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,391</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,349</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherOperatingIncomeExpenseNet_z6LUGJd1nhY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,801</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_zDIBqrphzEp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProfitLoss_zQdCgB7QgF9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,334</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,616</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zIOCUbsUWdu4" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49F_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zodOlESkAIJ7" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zrWGbkQ2clB8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_493_20210701__20210930_zu4wXbTkc2aj" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_401_ecustom--RevenuesExcludingOtherRevenue_zD4z3o6HlPsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">187</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,560</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InterestExpense_zReCNhp55DMk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_zFwFVtCorn5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_zRdTgmnLwvR8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">812</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_z1xW8B3emKC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,491</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,580</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zUjBrs6pAgea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_zotm7evHfhQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">513</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">513</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ProfitLoss_zW2HjkmUl0O" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,109</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,006</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,243</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_499_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zPPem6aIvnN9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_z5aOsmcEqyal" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_495_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zeCKteJWHRj9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_491_20220101__20220930_zB1n61cOHXfg" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_40F_ecustom--RevenuesExcludingOtherRevenue_zMDatdotNaAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueNotFromContractWithCustomerOther_zc7Bc4bKapH4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestExpense_zLQVkglm0OT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1076">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zgm3oR4Dc5la" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,173</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,173</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_zMvozKxtQmJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,964</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_zl9CDUF4uVQ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,527</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_zQLhUej8PKnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zoHihJmpXi42" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ProfitLoss_zJXoyzoPyhPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,373</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,976</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,738</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,659</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zO5LXqW8N5b8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zFglN0Db3m96" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zH6sYj2Ukmc5" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_494_20210101__20210930_zRp3YNvqb6Lh" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_407_ecustom--RevenuesExcludingOtherRevenue_z76esK9YQ6ee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,703</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueNotFromContractWithCustomerOther_zRvaqLmVlflb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestExpense_zZhk2Vhfp5B1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zI0ZXQjbEE4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationAndAmortization_zjvRCjzP2um" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_znB1cRe1wGvh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1136">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_zR6jjnsmo0pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherOperatingIncomeExpenseNet_zduVhr9vLDl8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1146">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_zCoMR9Th89cf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,980</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,980</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ProfitLoss_zYEAyfdB2TI6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,766</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(476</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,602</td><td style="text-align: left"> </td></tr> </table>
CY2022Q3 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
13613000 usd
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
1000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
82000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1792000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
634000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4349000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1801000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1942000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q3 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
9560000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
53000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2487000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3580000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
128000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
513000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
2243000 usd
swkh Disclosure Marketable Investments Details3 Abstract
DisclosureMarketableInvestmentsDetails3Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureMarketableInvestmentsDetails3Abstract_pn3n3_zveH3MNHtoD9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 3)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Unrealized net gain (loss) on equity securities reflected in the unaudited condensed consolidated statements of income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220701__20220930_zxlOGe33KxPb" style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210701__20210930_z7lM1XFXEW3d" style="width: 9%; text-align: right">342</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20220930_znt6PgayNuz2" style="width: 9%; text-align: right">(534</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20210930_zWoThvY8FO93" style="width: 9%; text-align: right">1,557</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
13000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
342000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-534000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1557000 usd
swkh Disclosure Intangible Assets Details Abstract
DisclosureIntangibleAssetsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zK7zX30gi3c1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Book Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-size: 10pt">Licensing Agreement<sup id="xdx_F44_z1prfJbPrjOg">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zWmNXuk9g077" style="width: 5%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zuMwzbt86fW8" style="width: 5%; text-align: right">21,096</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zeyZXJ3JL7V8" style="width: 5%; text-align: right">8,304</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zUr5tCsVtNqb" style="width: 5%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zWqTRVG8JJt1" style="width: 5%; text-align: right">19,780</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zs8xRMD63909" style="width: 5%; text-align: right">9,620</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcFbX7ksyHdb" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcWtbZLDX0Tb" style="text-align: right">65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypqG3lP37se" style="text-align: right">145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zL7cgGBLFpPj" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zAvz5ZLaCdJ3" style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zuGEBLoL77Ad" style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zyoh415KPEVh" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zL87bbbGkyak" style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsCurrent_iI_c20220930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6dEb4CWLMN7" style="border-bottom: Black 1pt solid; text-align: right">166</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNYQc9KNO8ih" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zmiPzAlS9eW2" style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znimLEFS7p88" style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220930_zPMw1mIoG54f" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220930_zlgVMqRBRjG3" style="border-bottom: Black 2.5pt double; text-align: right">21,235</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20220930_zlrhluWs60Te" style="border-bottom: Black 2.5pt double; text-align: right">8,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231_zU0sXUVzEnx" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zyeSyebxMTZe" style="border-bottom: Black 2.5pt double; text-align: right">19,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20211231_zHGeK0WfM5j3" style="border-bottom: Black 2.5pt double; text-align: right">9,964</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"/><td style="width: 20pt; text-align: left"><span id="xdx_F05_zlQn9eUd1Qra" style="font-size: 8pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F1D_zuiNSrej2QWb" style="font-size: 8pt">Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA<sup>TM</sup> in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.</span></td> </tr></table>
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21235000 usd
CY2022Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
8615000 usd
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19886000 usd
CY2021Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
9964000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2900000 usd
swkh Disclosure Intangible Assets Details2 Abstract
DisclosureIntangibleAssetsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zAyAYBn4dHof" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20220930_z1LLX2Ll5LSd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_z8njqN3uwKdb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%">Remainder of 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">426</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zRrpxh6lQns3" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">2023</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zO7lFdfv7Sn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">2024</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zJgI27JTlard" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">2025</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zIjTbV1LiVEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">2026</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_zfrBa7ki5Jah" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,788</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zri3Ij75FPD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 6pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,615</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
426000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1703000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1546000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1076000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1076000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2788000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8615000 usd
CY2021Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
8500000 usd
CY2022Q3 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
8500000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
53000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2487000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3580000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
128000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
513000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
2243000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
31206000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
481000 usd
us-gaap Interest Expense
InterestExpense
242000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5173000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1964000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10527000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
89000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3211000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
40703000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
496000 usd
us-gaap Interest Expense
InterestExpense
292000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5577000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3305000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9825000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2235000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4980000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
89000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3211000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
31206000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
481000 usd
swkh Disclosure Commitments And Contingencies Details Abstract
DisclosureCommitmentsAndContingenciesDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zehJQ1JNPd86" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"/><td/> <td style="text-align: left"/><td id="xdx_480_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zNErjL9w8bK1" style="text-align: right"/><td style="text-align: left"/></tr> <tr id="xdx_418_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AziyoBiologicsIncMember_zHUhl0Rvqmsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Aziyo Biologics, Inc.</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExeevoIncMember_zG7t6ujfSXol" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exeevo, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedMinderSystemsIncMember_zKXeCsWwVOS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">MedMinder Systems, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrioHealthcareLtdLoanMember_zcj95hAPwVqb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Trio Healthcare Ltd. Loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1.4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20220930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zLy5nAVf1J16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 15pt">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details Abstract
DisclosureFairValueMeasurementsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zgNsL7LcTh69" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kym4jozEb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRvOkVxGBaz6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49A_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z8JpOiT4lbv3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjnfNuilXj41" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zSo1MTPD4S59" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zwc58hDNugNc" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">Warrant assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zbfj2mOEPKa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0762">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zM3aJMTVqMOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_zyNmApykTbUk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_495_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPoMZQigPIP" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4m4rM7WBtcb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zznThFXqX19j" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE7Rs79yxDO9" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_401_ecustom--FinancialAssetsAbstract_iB_z4lcoFdz0bm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WarrantAssets_i01I_pn3n3_zARKl8wU721i" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">Warrant assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zeFOe4u8JUz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FinancialLiabilitiesAbstract_iB_zCsjJzHH1EY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z0tx5HHum2Dh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0796">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details2 Abstract
DisclosureFairValueMeasurementsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zcHzJG7hG99d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49F_20220101__20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zl6Qzmzquxa5" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_497_20210101__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpSdLPytuBhe" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td></tr> <tr id="xdx_401_ecustom--WarrantAssets_iS_zNOUl4GuI4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Fair value - December 31, 2021</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 32%">Fair value - December 31, 2020</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WarrantIssuances_zwh9YsaA8La9" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,098</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WarrantsCanceled_zvVJETzA36Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">—</span></td><td style="text-align: left"> </td><td> </td> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_zPyVkjPCfXVf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">623</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantAssets_iE_z3kQmfbmwg36" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value - September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details3 Abstract
DisclosureFairValueMeasurementsDetails3Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_zRukTnGL9V9g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left">Dividend rate range</td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z9t3ciIW5P2l">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zRmCddQ9nt3b"><span style="-sec-ix-hidden: xdx2ixbrl0823">—</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5OiMKygyGSj">4.0%</span> to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zL67Azf1L5F9">4.3%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ztBxqdTzxIU1">0.97%</span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zgskL4gtK2s1">1.44%</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"> <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z1SlK6ngUGTd" title="::XDX::P1Y9M18D">1.8</span> to <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zv2dr8bQmXX1" title="::XDX::P6Y10M24D">6.9</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUGo3Cdo1nW" title="::XDX::P2Y7M6D">2.6</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zZnFB87NuPsg" title="::XDX::P7Y">7.0</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ztttiiX1FL36">54.8%</span> to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zwQzhDkXxvX1">139.4%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zkvI7Uu81DFj">60.2%</span> to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zbUSmoOrFFdc">142.0%</span></span></td><td style="text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1801000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1942000 usd
swkh Disclosure Fair Value Measurements Details4 Abstract
DisclosureFairValueMeasurementsDetails4Abstract
<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zWg6TR2SUDp5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zVOCVYBsVjkj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Total </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value in </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Consolidated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>Sheets</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_ze2hMWpFjAoj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Quoted Prices </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>in Active </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identical </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or Liabilities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zmmIER4zuUea" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Other </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Observable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zBxMMxaW8z7b" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unobservable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Inputs </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>(Level 3)</b></p></td></tr> <tr id="xdx_43B_c20220930_eus-gaap--InvestmentsFairValueDisclosure_iI_z91Gfg0F53Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 47%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>September 30, 2022</b></span></td><td style="vertical-align: bottom; width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,071</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,071</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left"> </td><td style="vertical-align: bottom; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20211231_eus-gaap--InvestmentsFairValueDisclosure_iI_zUEb0txOiOOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="vertical-align: bottom; font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Fair Value Measurements Details5 Abstract
DisclosureFairValueMeasurementsDetails5Abstract
<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_zluFICpcHkW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20220930__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zdgLPrxXxa8c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49F_20220930__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zWy7KRyduKza" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z47bZgnQYe36" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_496_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK7kAiQB6Ow5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49C_20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1QhLOwYNoWl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr> <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zmyHAlMozf7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z4mQgulvUwe9" style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansReceivableFairValueDisclosure_i01I_zRgphdbR2h6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,959</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentsFairValueDisclosure_i01I_zxtSy9W0IOG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zFfXh7VsI7pd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAbstract_iB_zDgfQGnHK25k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ContingentConsiderationPayable_i01I_zrOBqoMx6DSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_z7gXcs9uBTcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zk01Je4oUxW6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsr5oTcNRo4l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLqnyeGEL9M6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZxzxRAvuzD" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr> <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zuEea5mcJME8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z2DXxKTVmf5b" style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansReceivableFairValueDisclosure_i01I_z0g9Sgofqtcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0912">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InvestmentsFairValueDisclosure_i01I_zyZA3zM5912h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAssetsFairValueDisclosure_i01I_za7VQ2hFpii1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0923">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesAbstract_iB_zKG4xeuipIh3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContingentConsiderationPayable_i01I_zfSkAAENqGi7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
swkh Disclosure Revenue Recognition Details Abstract
DisclosureRevenueRecognitionDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_ztnH6eYmRjq7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td/><td style="padding-bottom: 1pt"/> <td style="text-align: center"/> <td id="xdx_49D_20220701__20220930_zdjiRNYgl3Yh" style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td id="xdx_491_20210701__20210930_zQwWR1vRryYf" style="text-align: center"/> <td style="text-align: center"/><td style="padding-bottom: 1pt"/> <td style="text-align: center"/> <td id="xdx_49D_20220101__20220930_zpeNVcfR5my3" style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td style="text-align: center"/> <td id="xdx_490_20210101__20210930_zGA6k0vDTSpa" style="text-align: center"/> <td style="text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1.5pt; text-align: center"><b>September 30,</b></p></td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z4KDjTJGUw7f" style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left">License Agreement<sup id="xdx_F4C_zFaZggirAYbh">(1)</sup></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,103</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,235</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zkKVLp6kcNc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">556</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zoX5f5oMPYcd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td id="xdx_F0A_z3ZTGT0bgK33" style="width: 20pt">(1)</td> <td id="xdx_F18_zqnu4xb0n6Qa">$<span id="xdx_90B_eus-gaap--RevenueRecognitionMilestoneMethodRevenueRecognized_dm_c20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--EnterisLicenseAgreementMember_zKR7ers9iFRh">5.0 million</span> of milestone revenue related to Enteris’s License Agreement with Cara was received during the nine months ended September 30, 2022.</td></tr> </table>
swkh Disclosure Revenue Recognition Details2 Abstract
DisclosureRevenueRecognitionDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_zeJFfJwX4gRc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_490_20220930_zFLCsCFKZbbh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20211231_zGY096OVsGK5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zOMsHWPehNd1" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">8</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">185</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_znnbjY5BjSqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
8000 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
185000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
185000 usd
swkh Disclosure Segment Information Details Abstract
DisclosureSegmentInformationDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_zGUXhgt5o8Q5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td><b/></td><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_491_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zipfofcpN65k" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_497_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zogLvKUeRVw8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_493_20220701__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zmEbE7qtXlH9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_492_20220701__20220930_z5VzOdv2hvyl" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_40E_ecustom--RevenuesExcludingOtherRevenue_z6j2EcB6ljil" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,502</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueNotFromContractWithCustomerOther_zKkyeWAQ4jM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpense_zsmrVLQ2kjS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zqs04zPAfnY5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DepreciationAndAmortization_z27gtj4l6o4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">634</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_z2NdSEDrqzjf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,391</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,349</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherOperatingIncomeExpenseNet_z6LUGJd1nhY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,801</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_zDIBqrphzEp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProfitLoss_zQdCgB7QgF9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,334</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,616</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zIOCUbsUWdu4" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49F_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zodOlESkAIJ7" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20210701__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zrWGbkQ2clB8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_493_20210701__20210930_zu4wXbTkc2aj" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_401_ecustom--RevenuesExcludingOtherRevenue_zD4z3o6HlPsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">187</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,560</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InterestExpense_zReCNhp55DMk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_zFwFVtCorn5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_zRdTgmnLwvR8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">812</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_z1xW8B3emKC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,491</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,580</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zUjBrs6pAgea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_zotm7evHfhQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">513</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">513</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ProfitLoss_zW2HjkmUl0O" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,109</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,006</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,243</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_499_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zPPem6aIvnN9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_z5aOsmcEqyal" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_495_20220101__20220930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zeCKteJWHRj9" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_491_20220101__20220930_zB1n61cOHXfg" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_40F_ecustom--RevenuesExcludingOtherRevenue_zMDatdotNaAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueNotFromContractWithCustomerOther_zc7Bc4bKapH4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestExpense_zLQVkglm0OT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1076">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zgm3oR4Dc5la" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,173</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,173</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_zMvozKxtQmJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,964</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_zl9CDUF4uVQ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,527</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_zQLhUej8PKnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zoHihJmpXi42" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ProfitLoss_zJXoyzoPyhPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,373</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,976</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,738</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,659</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zO5LXqW8N5b8" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_498_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zFglN0Db3m96" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_49A_20210101__20210930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zH6sYj2Ukmc5" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/> <td id="xdx_494_20210101__20210930_zRp3YNvqb6Lh" style="font-weight: bold; text-align: center"/> <td style="font-weight: bold; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Receivables</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Company and Other</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td></tr> <tr id="xdx_407_ecustom--RevenuesExcludingOtherRevenue_z76esK9YQ6ee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,703</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueNotFromContractWithCustomerOther_zRvaqLmVlflb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestExpense_zZhk2Vhfp5B1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zI0ZXQjbEE4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationAndAmortization_zjvRCjzP2um" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_znB1cRe1wGvh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1136">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_zR6jjnsmo0pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherOperatingIncomeExpenseNet_zduVhr9vLDl8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1146">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_zCoMR9Th89cf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,980</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,980</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ProfitLoss_zYEAyfdB2TI6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,766</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(476</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,602</td><td style="text-align: left"> </td></tr> </table>
CY2022Q3 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
13613000 usd
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
1000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
82000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1792000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
634000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4349000 usd
us-gaap Interest Expense
InterestExpense
242000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5173000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
6616000 usd
CY2021Q3 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
9560000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1964000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10527000 usd
us-gaap Profit Loss
ProfitLoss
10659000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
40703000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
496000 usd
us-gaap Interest Expense
InterestExpense
292000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5577000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3305000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-147000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9825000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2235000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4980000 usd
us-gaap Profit Loss
ProfitLoss
19602000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001552781-22-000629-index-headers.html Edgar Link pending
0001552781-22-000629-index.html Edgar Link pending
0001552781-22-000629.txt Edgar Link pending
0001552781-22-000629-xbrl.zip Edgar Link pending
e22490001.jpg Edgar Link pending
e22490_ex10-1.htm Edgar Link pending
e22490_ex10-2.htm Edgar Link pending
e22490_ex31-1.htm Edgar Link pending
e22490_ex31-2.htm Edgar Link pending
e22490_ex32-1.htm Edgar Link pending
e22490_ex32-2.htm Edgar Link pending
e22490_swkh-10q.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
e22490_swkh-10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
swkh-20220930.xsd Edgar Link pending
swkh-20220930_cal.xml Edgar Link unprocessable
swkh-20220930_def.xml Edgar Link unprocessable
swkh-20220930_lab.xml Edgar Link unprocessable
swkh-20220930_pre.xml Edgar Link unprocessable